Post-earnings recap
Reported
Thu, Jul 30, 2026
EPS actual
$0.70
EPS est.
$0.61
EPS surprise
+15.51%
1-day move
-0.80%
DexCom's earnings report showed a positive surprise in EPS, exceeding expectations by a notable margin. However, the stock reacted negatively, declining by 0.8%. The lack of revenue data and management commentary may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.70 | $0.67 | +15.51% |
| Revenue | N/A | $1.3B | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes. As part of the health care equipment sector, DexCom plays a crucial role in improving diabetes management and patient outcomes, particularly as the prevalence of diabetes continues to rise globally.
Last quarter
In Q1 2026, DexCom reported an EPS of $0.56, exceeding analyst expectations by 19.66%. The stock reacted positively, gaining 3.46% the following day.
EPS beat streak
5Q
EPS beat rate
63%
Avg EPS surprise
+0.74%
Avg 1-day reaction
-0.02%
Analysts expect DexCom to report solid earnings this quarter, with a consensus EPS of $0.67 and revenue of $1.3 billion. The stock's performance will likely depend on whether the company can meet or exceed these expectations.
Bull case
If DexCom beats earnings expectations, it could signal strong demand for its products and improved market position, potentially leading to a positive stock reaction.
Bear case
Conversely, if the company misses its earnings targets, it may raise concerns about sales growth and market competition, leading to a negative impact on the stock price.
Key metrics to watch
EPS
0.67Earnings per share is a key indicator of profitability and helps gauge the company's financial health.
Revenue
1.3BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will DexCom achieve an EPS of $0.67 or higher?
This specific EPS target is crucial for investor confidence and could determine the stock's immediate reaction.
Q2
What insights can management provide about revenue growth trends?
Understanding revenue growth will help gauge the company's market position and future prospects.
Est. EPS
—
Est. Rev
—
Impl. Move
±18.3%
Why consensus could be wrong
The consensus may underestimate the impact of new product launches and market expansion efforts, which could drive higher sales than anticipated.
Supporting evidence
Recent trends show increasing adoption of continuous glucose monitoring systems, which could boost revenue.
The options market is pricing in a larger move than historical averages, indicating potential for a significant reaction.
The company's recent performance has shown resilience despite market challenges.
Key risk
If revenue growth exceeds expectations, it could invalidate the cautious outlook currently held by analysts.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal in determining whether DexCom can maintain its growth momentum in a competitive market.
Bull confirmed if
An EPS of $0.70 or better would confirm strong demand and operational efficiency.
Bear confirmed if
An EPS below $0.62 would raise concerns about the company's growth trajectory.
What the market is pricing for the move.
Implied Move
±14.1%
Historical Avg
±1.8%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±14.1% while DXCM has averaged ±1.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
46.5%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$220,974.75
2,565 sh
1 insider
Net
$220,974.75
Net selling
Most Active Insiders· 1 open-market trade
$220,974.75
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
106.71%
of float
Insider
0.26%
of float
Holders
1,463
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
38,244,137 sh · $3.2B
10.13%
-1.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If DexCom beats expectations, history suggests a potential stock increase of around 1% on the day following the report.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in management's commentary.
Miss
A miss on earnings could lead to a decline in stock price, with historical patterns suggesting a drop of approximately 0.65%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
0 buys·2 sells
Members
1
Senate only
Est. Notional
$200,002.00–$500,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
Recent Transactions
Sep 28, 2026 · @ $86.15
2,565 sh
$220,974.75
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Vanguard Capital Management LLC
25,209,752 sh · $2.1B
6.68%
0.8%
Vanguard Portfolio Management LLC
19,656,540 sh · $1.7B
5.21%
2.3%
State Street Corporation
18,380,806 sh · $1.5B
4.87%
2.5%
Invesco Ltd.
15,288,133 sh · $1.3B
4.05%
11.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded May 7, 2026 · disclosed May 10, 2026
$100,001.00–$250,000.00
Traded Apr 29, 2026 · disclosed May 10, 2026
$100,001.00–$250,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.